Effect of Long-Term Use of Tenofovir (TDF) on Bone Density in Patients With Chronic Hepatitis B

Launched by ASSIUT UNIVERSITY · May 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the long-term effects of a medication called Tenofovir Disoproxil Fumarate (TDF) on bone health in people with chronic hepatitis B. TDF is commonly used to treat hepatitis B, but there are concerns that using it for a long time might harm bone density, which could lead to conditions like osteopenia or osteoporosis (weakened bones). The researchers want to find out if patients who have been taking TDF for more than five years have lower bone density compared to those who haven’t, using special scans to check bone health.

To participate in this study, you need to be an adult between the ages of 18 and 60, have a positive diagnosis for hepatitis B, and have been on TDF for over five years. Unfortunately, people with other chronic liver diseases, chronic kidney disease, or those on certain combination therapies won't be eligible. If you decide to join, you can expect to undergo health evaluations and bone scans to help determine the impact of TDF on your bones. This important research will help doctors understand the long-term safety of TDF and make better treatment decisions for patients with chronic hepatitis B.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -
• Inclusion Criteria:
• • Adult male or female patients aged 18 to 60 years.
• • Diagnosed as HBV-positive.
• • Long-term use of Tenofovir Disoproxil Fumarate (TDF) for more than five years.
• Exclusion Criteria:
• • Presence of other chronic liver diseases.
• • Diagnosed with Chronic Kidney Disease (CKD), regardless of etiology.
• • Patients who refuse to participate in the study.
• Patients on combination therapy, including:
• • Interferon and Nucleoside analogue combination therapy.
• • Multiple nucleoside analogue combination therapy.
• • -